期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

硼替佐米联合化疗治疗多发性骨髓瘤的临床分析 被引量：1

下载PDF
导出
摘要 多发性骨髓瘤（MM）是B细胞来源的恶性肿瘤，它影响产生免疫球蛋白的浆细胞，是血液系统第二常见恶性肿瘤。目前的传统化疗方案有效率为70％，但完全缓解（CR）率不高。新药硼替佐米是蛋白酶体抑制剂，它和多种化疗药物如地塞米松、阿霉素等联合，具有疗效叠加及协同效应，使初治MM的完全缓解或接近完全缓解（CR／nCR）率达到25％[1,2]。我们以硼替佐米为主要药物治疗了30例MM患者，观察其疗效及不良反应．现报告如下。
作者 蒋玉梅 王松梅
机构地区 山东省烟台市食品药品监督管理局福山区分局 青岛大学医学院附属青岛市市立医院东院血液科
出处 《中国药物与临床》 CAS 2011年第9期1077-1078,共2页 Chinese Remedies & Clinics
关键词 多发性骨髓瘤 硼替佐米 药物治疗 临床分析 联合化疗 蛋白酶体抑制剂 完全缓解 恶性肿瘤
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献6

  • 1Jagannath S, Durie B, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol,2005,129:776- 7831.
  • 2Caravita T, de Fabritiis P, Palumbo A, et al. Bortezomib : efficacy comparisons in solid tumors and hematologic malignancies. Nat Clin Pract Oncol, 2006,3 (7) : 374-387.
  • 3Mitsiades N, Mitsiades CS,Richardson PG,et al. The proteasome inhibitor PS2341 potentiatessensitivity of multiple myeloma cells to conventionalchemotherapeutic agents: therapeutic applications. Blood, 2003, 101 : 2377-2380.
  • 4Ma MH,Yang HH,Parker K,et al. The proteasome inhibitor PS2341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res,2003,9: 1136-1144.
  • 5Kropff MH, Bisping G,Wenning D,et al. Bortezomib in combina- tion with dexamethasooe for relapsed multiple myeloma. Leuk Res, 2005,29(5) : 587-590.
  • 6王丽霞,陆化,沈文怡,钱思轩,仇红霞,吴汉新,张建富,吴雨洁,李建勇.硼替佐米联合地塞米松治疗多发性骨髓瘤的临床研究[J].中国实验血液学杂志,2008,16(4):943-945. 被引量：17

二级参考文献6

  • 1Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med, 2003 ; 348 : 2609 - 2617
  • 2Kropff MH, Bisping G, Wenning D, et al. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res, 2005 ; 29 : 587 - 590
  • 3Jagannath S, Richardson PG, Barlogie B, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica, 2006; 91: 929- 934
  • 4Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood, 2003; 101:2377-2380
  • 5Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol, 2005 ; 129 : 776 - 783
  • 6Oakervee HE, Popat R, Curry N, et al. PAD combination therapy ( PS-341/bortezomib, doxorubicin and dexamethasone ) for previously untreated patients with multiple myeloma. Br J Haematol, 2005 ; 129 : 755 - 762

共引文献16

同被引文献12

  • 1Qu Y,Mu GY,Wu YW,et al.Overexpression of DNA Methyl-transferases1,3a,and3b significantly correlates with retinoblas-toma tumorigenesis.Am J Clin Pathol,2010,134:826-834.
  • 2Liu SJ,Liu ZF,Xie ZL,et al.Bortezomib induces DNA hy-pomethylation and silenced gene transcription by interfering with Sp1/NF-κB dependent DNA methyltransferase activity in acute myeloid leukemia.Blood,2008,111:2364-2373.
  • 3Subramanyam D,Belairl CD,Barry-Holson KQ,et al.PML-RAR(alpha)and Dnmt3a1cooperate in vivo to promote acute promye-locytic leukemia.Cancer Res,2010,70:8792-8801.
  • 4Ghoshal K,Bai S.DNA methyltransferases as targets for cancer therapy.Drugs Today(Barc),2007,43(6):395-422.
  • 5Liu S,Shen T,Huynh L,et al.Interplay of RUNX1/MTG8and DNA methyltransferase1in acute myeloid leukemia.Cancer Res,2005,65:1277-1284.
  • 6Jung Y,Park J,Kim TY,et al.Potential advantages of DNA methyltransferases-1(DNMT1)-targeted inhibition for cancer therapy.J Mol Med,2007,85(10):1137-1148.
  • 7Jiemjit A,Fandy TE,Carraway H,et al.p21(WAF1/CIP1)in-duction by5-azacytosine nucleosides requires DNA damage.Oncogene,2008,27(25):3615-3623.
  • 8Kishikawa S,Murata T,Kimura H,et al.Regulation of transcrip-tion of the DNMT1gene by Sp1and Sp3zinc finger proteins.Eur J Biochem,2002,269:2961-2970.
  • 9Zhu W,Srinivasan K,Dai Z,et al.Methylation of adjacent CpGsites affects SplPSp3binding and activity in the p21(Cipl)promoter.Mol Cell Bio,2003,23(12):4056-4065.
  • 10Sarraj A,Day RM,Thiel G,et al.Specificity of transcriptional regulation by the zinc finger transcription factors Sp1,Sp3.Cell Biochem,2005,94(1):153-167.

引证文献1

中国药物与临床
2011年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部